Cirrus Therapeutics

Understanding Dry AMD: From Early Signs to Advanced Stages Dry age-related macular degeneration (AMD) progresses through three key stages—early, intermediate, and late (geographic atrophy)—each marked by a build-up of drusen, which are yellow deposits beneath the retina.   1. Early Stage Dry AMD: Characterized by small to medium-sized drusen (yellow deposits beneath the retina), often without noticeable symptoms. Patients might have slight difficulty with tasks requiring fine vision like reading 2. Intermediate Stage Dry AMD: More drusen accumulate, leading to potential blurriness in central vision. Many begin to notice challenges with reading or seeing in low light. 3. Late Stage Dry AMD (Geographic Atrophy): Significant damage to the retinal cells, resulting in noticeable blind spots in the central vision. This stage can greatly impair daily activities and quality of life.   At Cirrus Therapeutics, we’re pioneering a novel approach that targets multiple pathways in AMD, using gene therapy to increase IRAK-M protein levels. Our treatment has the potential to significantly slow or even prevent retinal degeneration, offering hope to millions worldwide affected by dry AMD.   Stay tuned for updates on our journey to bring this groundbreaking therapy to patients and transform vision care for the future. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM Ying Kai Chan Andrew Dick

Did you know that smoking can not only harm your lungs but also eventually affect your eyesight? While the numbers have decreased, studies show that more than 36 million U.S. adults still smoke cigarettes. Smokers face a higher risk of developing Age-related Macular Degeneration (AMD) up to a decade earlier than non-smokers, with the disease progressing more rapidly and responding less effectively to treatments. At Cirrus Therapeutics, we are pioneering a groundbreaking approach to combat AMD by targeting the critical protein IRAK-M, which protects retinal cells and slows degeneration. Our unique, first-in-class therapy is designed to address multiple pathways of the disease, offering a new hope beyond current treatments which target only single aspects of AMD. Join us on our journey to revolutionize ocular health. Follow our updates as we advance towards translation and aim to improve the lives of patients worldwide. Your support and interest help fuel our commitment to a healthier, clearer future. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM

Early detection is key when it comes to preserving vision health. One simple yet powerful diagnostic tool eye professionals use to monitor changes in central vision is the Amsler Grid. It's a square grid with a dot in the center—sounds simple, but when used correctly, it can help detect early signs of Age-Related Macular Degeneration (AMD), a leading cause of vision loss in older adults. It’s also extremely helpful finding urgent Wet AMD issues.    Here's how it works: hold the grid about 12-15 inches away, cover one eye, and focus on the center dot. If any lines appear wavy or if you notice blank spots, it could be an early sign of AMD. This proactive, routine check can be critical in protecting long-term eye health.   At Cirrus Therapeutics, we're deeply committed to promoting vision care and taking this fight against Dry AMD a step further. While the Amsler Grid offers early detection, our innovative treatment approach targets the underlying causes of dry AMD by addressing multiple pathways in retinal degeneration. Our primary program focuses on a groundbreaking strategy to protect retinal cells, offering hope to the millions affected by this condition.   Follow us on our journey toward translation, as we work to revolutionize eye care and bring new solutions to patients worldwide. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM Ying Kai Chan Andrew Dick

October marks National Vision Awareness Month, a crucial time to emphasize the importance of eye health and vision care. At Cirrus Therapeutics, we recognize the need for awareness about common eye conditions such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy.   This month, we encourage everyone to prioritize regular eye exams, as early detection is key to preventing vision loss. By adopting healthy habits like protecting your eyes from UV rays and maintaining a balanced diet, we can all take proactive steps towards better eye health.   As we spotlight the significance of vision care, we’re also proud to support ongoing research and development aimed at advancing treatments for eye diseases. Our innovative approach focuses on dry age-related macular degeneration (AMD), a leading cause of vision loss in older adults. By leveraging the power of the IRAK-M protein, our goal is to improve the quality of life for those affected by this condition.   Join us on our journey to translate groundbreaking therapies that aim to enhance health span. Follow us for updates on our progress as we work to bring transformative solutions to patients worldwide. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM

The Impact of Dry Age-Related Macular Degeneration (AMD): Quality of Life As we look toward the future, it's estimated that millions will be affected by Dry AMD, a condition that profoundly impacts quality of life. More than 80% of individuals suffering from this disease report difficulties with essential daily activities such as reading, driving, and recognizing faces. This decline in visual function doesn't just impede their independence; it can lead to increased emotional and psychological distress and a heightened risk of falls, ultimately affecting their overall well-being. At Cirrus Therapeutics, we understand the urgency of addressing this growing health challenge. Our innovative approach leverages the protein IRAK-M to address the complex pathways involved in Dry AMD treatment. By enhancing retinal cell protection, we aim to transform the current landscape of AMD care, moving beyond conventional treatments that only target single pathways. With life expectancies extending, the long-term implications of Dry AMD are becoming increasingly severe. Our mission is clear: to improve the quality of life for this large segment of the global population through our groundbreaking treatments. We invite you to follow Cirrus Therapeutics on our journey to translation as we strive to transform the landscape of ocular health and provide solutions that truly matter. Together, we can help millions live healthier and more independent lives. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM #bio #biotech #asiansinbiotech

We are proud to share that Dr. Ying Kai Chan, CEO of Cirrus Therapeutics and a 2024 Termeer Fellow, attended the inaugural CEO & Founders Link event sponsored by MassBio and the The Termeer Foundation. The initiative is designed to foster collaboration and support among biotech leaders, providing a critical space for networking and exchanging insights.   "In our quest for innovation, it's vital to remember that every decision we make should center on the patients we serve. Community and collaboration are at the heart of what we do; together, we can overcome challenges and drive meaningful change in healthcare."   At Cirrus Therapeutics, we are committed to transforming the treatment landscape for dry age-related macular degeneration (AMD) through our pioneering approach centered on the IRAK-M protein.   Join us on this exciting journey toward translation as we strive to redefine ocular health and help patients around the world. Stay tuned for more updates on our progress! #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM

Did you know that Age-Related Macular Degeneration (AMD) is the leading cause of irreversible vision loss in individuals over 60? Starting as Dry AMD, this condition quietly progresses, with 10-15% of cases advancing to the Wet AMD, leading to sudden, significant vision loss. At Cirrus Therapeutics, we're tackling AMD head-on. Our cofounders, Dr. Ying Kai Chan and Dr. Andrew Dick, have pioneered a novel, first-in-class treatment focusing on Dry AMD—where it all begins. Our breakthrough involves enhancing the IRAK-M protein directly in retinal cells, offering a robust defense against degeneration. By addressing multiple degenerative pathways simultaneously, our approach doesn't just aim to treat AMD—it's designed to change the narrative on aging and vision health. Join us on our journey from groundbreaking science in the lab to life-changing impacts in clinics worldwide. Follow Cirrus Therapeutics for the latest updates on our path to translation and our mission to preserve vision for millions globally. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM

At Cirrus Therapeutics, we believe that developing transformative medical innovations is about more than just the science; it’s also about the dedicated people who bring the advancement to life. Our commitment to developing groundbreaking treatments for long-term eye diseases, like dry age-related macular degeneration (AMD), is powered by a team that embodies diversity, expertise, and a shared vision for profound patient impact.   Last week, our CEO and 2024 The Termeer Foundation Fellow, Dr. Ying Kai Chan participated in a two-day immersive fellowship program focused on strategic team building. The session reinforced the importance of fostering a resilient organizational culture that thrives on diversity and innovation. Insights gained are being integrated into our daily operations, ensuring that our team not only champions but also embodies the values necessary for true innovation in ocular immunology.   These efforts are critical as we advance our novel approach, targeting multiple pathways involved in AMD through the enhancement of the IRAK-M protein.   Stay tuned for more updates as we progress toward translation and continue making strides in helping patients with innovative, effective treatments. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM

At Cirrus Therapeutics, every day marks a new milestone in our quest to conquer age-related macular degeneration (AMD). The team's dedication to discovery comes to life in our state-of-the-art labs where collaboration meets innovation,  forging a path to groundbreaking treatments. "Working here isn’t just about the science; it’s about creating real-world solutions that will one day improve the lives of millions globally," shares Dr. Sumeet Sarin, Project Lead at Cirrus. "The energy here is electric—we're not just studying the disease, we're actively fighting it with every experiment, every breakthrough." Cirrus, born from the pioneering spirits of Cofounders Dr. Ying Kai Chan and Dr. Andrew Dick, is championing a novel approach to treating AMD by enhancing the IRAK-M protein in retinal cells, promising a significant advancement in available therapies. ➡️ Follow us on our journey as we bring visionary science from the lab to the lives of patients around the world. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM

As we wrap up Healthy Aging Month, it's important to highlight how lifestyle choices significantly impact our long-term health, particularly vision. Age-related macular degeneration (AMD) remains the leading cause of vision loss in older adults, but proactive measures can make a difference. Choices such as maintaining a Mediterranean diet, quitting smoking, protecting your eyes from UV rays, and regular eye exams are more than just health tips—they are preventive strategies against AMD. At Cirrus Therapeutics, we're taking these strategies a step further. Under the leadership of Dr. Kai Chan and Dr. Andrew Dick, our research focuses on a groundbreaking approach to treating AMD by boosting the IRAK-M protein in retinal cells. This innovative therapy not only addresses the underlying causes of AMD but also paves the way for a future where we can protect and prolong vision as we age. As we continue our journey towards translation and patient care, we invite our community of patients, physicians, and drug developers to stay updated and engaged. Let's keep our eyes on a healthier, brighter future! Stay tuned for updates on our path to bringing this innovative treatment to those in need around the world. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM #healthyaging #healthyagingmonth